Intellia Therapeutics Updates on Nex-Z Clinical Hold Following Patient Death in Phase 3 ATTR Trial

summarizeSummary

Intellia Therapeutics provided an update on the clinical hold for its nexiguran ziclumeran (nex-z) Phase 3 trials, following a patient death and Grade 4 liver transaminase elevations, while also highlighting progress in its Lonvo-z program.

check_boxKey Events

• Clinical Hold on Nex-z Trials

  The FDA placed a clinical hold on the Phase 3 MAGNITUDE and MAGNITUDE-2 trials for nexiguran ziclumeran (nex-z) due to safety concerns.

• Patient Death Reported

  A patient in the MAGNITUDE trial, who experienced Grade 4 liver transaminase elevations, subsequently died from septic shock secondary to a perforated duodenal ulcer.

• Safety Event Context

  Grade 4 liver transaminase elevations were reported in less than one percent of MAGNITUDE patients, with most resolving without sequelae, but the patient death is a serious adverse event.

• Regulatory Path Forward

  Intellia Therapeutics is working with regulators to finalize a plan for the nex-z program.

auto_awesomeAnalysis

The 8-K filing details the ongoing clinical hold on Intellia's pivotal Phase 3 MAGNITUDE and MAGNITUDE-2 trials for nexiguran ziclumeran (nex-z), a gene-editing therapy for ATTR amyloidosis. This hold was initiated after a patient experienced Grade 4 liver transaminase elevations and subsequently died due to septic shock secondary to a perforated duodenal ulcer, following a complicated clinical course that included acute liver injury. While the company notes that Grade 4 liver transaminase elevations occurred in less than one percent of patients and resolved in most cases, the clinical hold on a late-stage program represents a significant setback, introducing uncertainty and potential delays for a key pipeline asset. Investors will closely monitor the company's discussions with regulators for a clear path forward. The filing also included a corporate presentation that provided positive updates on the Lonvo-z program for hereditary angioedema, which is progressing towards a BLA submission in the second half of 2026.